Holen Sie sich die Stockscreener-App
18.60
2.37%
0.43
Handel nachbörslich:
18.60
Omada Health Inc Aktie (OMDA) Neueste Nachrichten
Omada Health to Participate in Evercore Healthcare Conference - The Manila Times
United States 7MM Digital Therapeutics for Diabetes Market: FDA - openPR.com
Omada Health’s Strategic Growth and Profitability: A Buy Rating by Craig Hettenbach - TipRanks
OMDA: BMO Capital Initiates Coverage with "Outperform" Rating | - GuruFocus
Thought bubble: Omada's about-face - Axios
Omada Health initiated with an Outperform at BMO Capital - TipRanks
Omada Health Positioned for Growth with Strong Financial Performance and Strategic Market Opportunities - TipRanks
EBIT per share of Omada Health, Inc. – MUN:U76 - TradingView
Inside Omada's pivot toward GLP-1 prescriptions - Axios
Cash from financing activities of Omada Health, Inc. – FWB:U76 - TradingView
Omada Health Reports Strong Q3 2025 Growth - MSN
How Trump’s GLP-1 move may affect telehealth companies’ fortunes - Modern Healthcare News
Free cash flow per share of Omada Health, Inc. – MUN:U76 - TradingView
Omada Health, Inc. Earnings and Revenue – MUN:U76 - TradingView
Omada Health (OMDA): Assessing Valuation After Recent Stock Declines - Yahoo Finance
Latin America Digital Therapeutics Market Poised - openPR.com
Omada Health Stock Jumps Into Retail Focus As Wall Street Lifts Price Targets After ‘Beat And Raise’ Quarter, GLP-1 Push - Stocktwits
Omada Health, Inc. Balance Sheet – FWB:U76 - TradingView
Omada Health raises FY25 revenue view to $251.5M-$254.5M from $235M-$241M - MSN
Omada Health reports Q3 EPS (6c), consensus (7c) - MSN
Omada Health Reports Strong Growth and Innovation - MSN
Omada Health price target raised to $32 from $30 at Morgan Stanley - MSN
Omada Health price target raised to $28 from $27 at Evercore ISI - MSN
Evercore ISI Group Maintains Omada Health (OMDA) Outperform Recommendation - MSN
Why Omada Health is finally prescribing Ozempic as TrumpRx slashes GLP-1 weight-loss drug costs - Business Insider
Omada Health Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Omada Health to prescribe GLP-1s - TechTarget
Evercore ISI Group Raises Price Target for OMDA to $28.00 | OMDA Stock News - GuruFocus
Omada Health, Inc.: Strong Revenue Momentum and Strategic Partnerships Drive Buy Rating - TipRanks
Omada Health to present RWE on behavior change program at ObesityWeek - MSN
Omada Health, Inc.: Strong Market Position and Growth Potential Drive Buy Rating - TipRanks
Omada Health Inc (OMDA) Q3 2025 Earnings Call Highlights: Record Membership Growth and ... By GuruFocus - Investing.com Canada
Omada Health Q3 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Omada Health Q3 2025 sees revenue growth, stock dips - Investing.com India
Omada Health announces GLP-1 prescribing capability - TipRanks
Compared to Estimates, Omada Health, Inc. (OMDA) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Omada Health announces GLP-1 prescribing capability to support growing member population - MarketScreener
Earnings Flash (OMDA) Omada Health, Inc. Reports Q3 Revenue $68.0M, vs. FactSet Est of $61.3M - MarketScreener
Omada Health, Inc. (OMDA) Q3 FY2025 earnings call transcript - Yahoo Finance
Omada Health Reports Third Quarter 2025 Results - The Manila Times
Omada Health Announces GLP-1 Prescribing Capability to Support Growing Member Population - The Manila Times
Omada Health (NASDAQ: OMDA) to offer GLP-1 prescribing nationwide; members up 53% YoY - Stock Titan
[8-K] Omada Health, Inc. Reports Material Event | OMDA SEC FilingForm 8-K - Stock Titan
Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows - CNBC
Earnings To Watch: Omada Health Inc (OMDA) Reports Q3 2025 Resul - GuruFocus
Earnings To Watch: Omada Health Inc (OMDA) Reports Q3 2025 Result - Yahoo Finance
Revenue per share of Omada Health, Inc. – NASDAQ:OMDA - TradingView
EBITDA per share of Omada Health, Inc. – SWB:U76 - TradingView
ETFs Investing in Omada Health, Inc. Stocks - TradingView
Omada Health (Nasdaq: OMDA) shows 0.8% after GLP-1 discontinuation, 63.2% maintained/lost - Stock Titan
Omada Health, Inc.: Strategic Growth and Market Penetration Drive Buy Rating - TipRanks
Omada Health, Inc. (NASDAQ:OMDA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Jennison Associates LLC Makes New Investment in Omada Health, Inc. $OMDA - MarketBeat
Omada Health, Inc. (OMDA) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Emerald Mutual Fund Advisers Trust Purchases Shares of 161,227 Omada Health, Inc. $OMDA - MarketBeat
11.42%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):